KINETICS AND MECHANISM OF THIOLYTIC CLEAVAGE OF THE ANTITUMOR COMPOUND 4'-(9-ACRIDINYL)AMINO) METHANESULFON-M-ANISIDIDEKHAN MN; MALSPEIS L.1982; J. ORG. CHEM.; ISSN 0022-3263; USA; DA. 1982; VOL. 47; NO 14; PP. 2731-2740; BIBL. 20 REF.Article

BIOTRANSFORMATION OF D(-)-EPHEDRINE AND L(+)-EPHEDRINE IN THE RABBIT IN VIVO AND IN VITRO.FELLER DR; MALSPEIS L.1977; DRUG METABOL. DISPOSIT.; U.S.A.; DA. 1977; VOL. 5; NO 1; PP. 37-46; BIBL. 36 REF.Article

A RAPID STABILITY-INDICATING HPLC ASSAY FOR THE ARABINOSYLCYTOSINE PRODRUG, CYCLOCYTIDINETUNCEL M; NOTARI RE; MALSPEIS L et al.1981; J. LIQ. CHROMATOGR.; ISSN 0148-3919; USA; DA. 1981; VOL. 4; NO 5; PP. 887-896; BIBL. 4 REF.Article

FACTORS AFFECTING THE QUANTITATIVE EVALUATION OF THE UNI- AND BIDIRECTIONAL REACTIONS OF MIXED LEUKOCYTE CULTURES = FACTEURS AFFECTANT L'EVALUATION QUANTITATIVE DES REACTIONS UNI- ET BIDIRECTIONNELLES DE CULTURES MIXTES DE LEUCOCYTESBOURONCLE BA; MALSPEIS L; ASCHENBRAND JF et al.1972; AMER. J. CLIN. PATHOL.; U.S.A.; DA. 1972; VOL. 58; NO 1; PP. 17-25; BIBL. 17REF.Serial Issue

Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidificationSUPKO, J. G; MALSPEIS, L.Journal of liquid chromatography. 1992, Vol 15, Num 18, pp 3261-3283, issn 0148-3919Article

IDENTIFICATION OF THE PRINCIPAL BILIARY METABOLITE OF 4'-(9-ACRIDINYLAMINO) METHANESULFON-M-ANISIDE IN RATSSHOEMAKER DD; CYSYK RL; PADMANABHAN S et al.1982; DRUG METAB. DISPOS.; ISSN 0090-9556; USA; DA. 1982; VOL. 10; NO 1; PP. 35-39; BIBL. 15 REF.Article

CLINICAL TOXIC EFFECTS OF 2,3-DIHYDRO-1H-IMIDAZO (1,2-B) PYRAZOLE (IMPY) WITH RELEVANT PHARMACOKINETIC PARAMETERSNEIDHART JA; STAUBUS AE; YOUNG D et al.1980; CANCER TREATM. REP.; USA; DA. 1980; VOL. 64; NO 2-3; PP. 251-255; BIBL. 7 REF.Article

METABOLISM OF THE EPHEDRINE ISOMERS IN RABBIT LIVERFELLER DR; BASU P; MELLON W et al.1973; ARCH. INTERNATION. PHARMACODYN. THERAP.; BELG.; DA. 1973; VOL. 203; NO 1; PP. 187-199; BIBL. 32REF.Serial Issue

Concurrent determination of merbarone and its urinary metabolites by reversed-phase HPLC with precolumn phenolic acetylationSUPKO, J. G; MALSPEIS, L.Journal of liquid chromatography. 1991, Vol 14, Num 11, pp 2169-2188, issn 0148-3919Article

HPLC analysis of merbarone (NSC 336628) in plasma using MG(II) as a mobile phase modifierMALSPEIS, L; SUPKO, J. G.Journal of liquid chromatography. 1990, Vol 13, Num 7, pp 1301-1319, issn 0148-3919Article

Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in miceSUPKO, J. G; MALSPEIS, L.Cancer research (Baltimore). 1993, Vol 53, Num 13, pp 3062-3069, issn 0008-5472Article

A rapid isocratic HPLC assay of suramin (NSC 34936) in human plasmaSUPKO, J. G; MALSPEIS, L.Journal of liquid chromatography. 1990, Vol 13, Num 4, pp 727-741, issn 0148-3919, 15 p.Article

Distribution of [2-¹⁴C]merbarone in mice by autoradiography of whole-body cryosectionsKEMMENOE, B. H; MALSPEIS, L.Cancer research (Baltimore). 1987, Vol 47, Num 4, pp 1135-1142, issn 0008-5472Article

ELIMINATION OF RADIOACTIVITY FOLLOWING ADMINISTRATION OF (15,16-³H) NALTREXONE TO RATS AND GUINEA PIGSLUDDEN TM; BATHALA MS; MALSPEIS L et al.1978; DRUG METABOL. DISPOSIT.; USA; DA. 1978; VOL. 6; NO 3; PP. 321-328; BIBL. 19 REF.Article

METABOLIC REDUCTION OF NALTREXONE. I. SYNTHESIS, SEPARATION AND CHARACTERIZATION OF NALOXONE AND NALTREXONE REDUCTION PRODUCTS AND QUALITATIVE ASSAY OF URINE AND BILE FOLLOWING ADMINISTRATION OF NALTREXONE, ALPHA -NALTREXOL, OR BETA -NALTREXOL. = REDUCTION METABOLIQUE DE LA NALTREXONE. I. SYNTHESE, SEPARATION ET CARACTERISATION DES PRODUITS DE REDUCTION DE LA NALOXONE ET DE LA NALTREXONE ET ANALYSE QUALITATIVE DE L'URINE ET DE LA BILE APRES ADMINISTRATION DE NALTREXONE, ALPHA -NALTREXOL OU BETA -NALTREXOLMALSPEIS L; BATHALA MS; LUDDEN TM et al.1975; RES. COMMUNIC. CHEM. PATHOL. PHARMACOL.; U.S.A.; DA. 1975; VOL. 12; NO 1; PP. 43-65; BIBL. 2 P.Article

TRITIATED NALTREXONE BINDING IN PLASMA FROM SEVERAL SPECIES AND TISSUE DISTRIBUTION IN MICE = LA FIXATION DE NALTREXONE TRITIEE DANS LE PLASMA DE PLUSIEURS ESPECES ET LA REPARTITION TISSULAIRE CHEZ LES SOURISLUDDEN TM; MALSPEIS L; BAGGOT JD et al.1976; J. PHARM. SCI.; U.S.A.; DA. 1976; VOL. 65; NO 5; PP. 712-716; BIBL. 25 REF.Article

Analysis of brefeldin A in plasma by gas chromatography with electron capture detectionPHILLIPS, L. R; SUPKO, J. G; MALSPEIS, L et al.Analytical biochemistry. 1993, Vol 211, Num 1, pp 16-22, issn 0003-2697Article

Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasmaSUPKO, J. G; PHILLIPS, L. R; MALSPEIS, L et al.Journal of chromatography. B, Biomedical applications. 1996, Vol 677, Num 2, pp 351-362Article

Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dogPHILLIPS, L. R; MALSPEIS, L; SUPKO, J. G et al.Drug metabolism and disposition. 1995, Vol 23, Num 7, pp 676-680, issn 0090-9556Article

An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluidsSTAUBUS, A. E; WEINRIB, A. B; MALSPEIS, L et al.Biochemical pharmacology. 1984, Vol 33, Num 10, pp 1633-1637, issn 0006-2952Article

TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA WITH 2'-DEOXYCOFORMYCIN: CLINICAL AND BIOCHEMICAL CONSEQUENCES OF ADENOSINE DEAMINASE INHIBITIONKOLLER CA; MITCHELL BS; GREVER MR et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 11-12; PP. 1949-1952; BIBL. 14 REF.Article

METABOLIC REDUCTION OF NALTREXONE. II. IN VITRO STUDIES USING LIVER FROM GUINEA PIG, MONKEY AND RAT.MALSPEIS L; LUDDEN TM; BATHALA MS et al.1976; RES. COMMUNIC. CHEM. PATHOL. PHARMACOL.; U.S.A.; DA. 1976; VOL. 14; NO 3; PP. 393-406; BIBL. 1 P. 1/2Article

Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detectionPHILLIPS, L. R; WOLFE, T. L; MALSPEIS, L et al.Journal of pharmaceutical and biomedical analysis. 1998, Vol 16, Num 8, pp 1301-1309, issn 0731-7085Article

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1BUCKHEIT, R. W; HOLLINGSHEAD, M; SHORES, R et al.AIDS research and human retroviruses. 1997, Vol 13, Num 9, pp 789-796, issn 0889-2229Article

A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2HOLMLUND, J. T; KOPP, W. C; MADARA, K et al.Journal of the National Cancer Institute. 1995, Vol 87, Num 2, pp 134-136, issn 0027-8874Article